Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco

Hepatology

Volumn 34, Issue 1, 2001, Pages 180-187

  Hahn, Judith A ^a,b   Page Shafer, Kimberly ^c   Lum, Paula J ^a   Ochoa, Kristen ^a   Moss, Andrew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; DRUG ABUSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INCIDENCE; INJECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEXUAL BEHAVIOR; UNITED STATES;

EID: 0034955890     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.25759     Document Type: Article

References (60)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
3. Hepatitis C virus transmission dynamics in injection drug users
4. Hepatitis C
5. Transmission of hepatitis C virus: Rates, routes, and cofactors
6. Correlates of hepatitis C virus infections among injection drug users
7. Hepatitis C virus infection in Italian intravenous drug users: Epidemiological and clinical aspects
8. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations
9. Epidemiology of hepatitis C virus infection among injecting drug users in Australia
10. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin
11. HCV, HIV, HBV, and HDV infections in intravenous drug addicts
12. Seroepidemiology of viral infections among intravenous drug users in northern California
13. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam
14. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme
15. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users
16. Risk factors for hepatitis C virus infection among injecting drug users in Sydney
17. Hepatitis C virus infection among a cohort of Victorian injecting drug users
18. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high
19. Hepatitis C virus in intravenous drug users
20. Blood-borne virus infections among Australian injecting drug users: Implications for spread of HIV
21. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.
22. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
23. Syringe exchange and risk of infection with hepatitis B and C viruses
24. Update syringe exchange programs - United States, 1997
25. The impact of intensive outreach on HIV prevention activities of homeless, runaway, and street youth in San Francisco: The AIDS Evaluation of Street Outreach Project (AESOP)
26. Satellite exchange in the Baltimore needle exchange program
27. Client-provided public health services: The case of secondary needle exchangers
28. Syringe and needle exchange as HIV/AIDS prevention for injection drug users
29. Epidemiology of hepatitis C in the United States
30. Risk of hepatitis B infection among young injection drug users in San Francisco: Opportunities for intervention
31. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco
32. Minimising harm from hepatitis C virus needs better strategies
33. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program
34. The multiperson use of non-syringe injection equipment and risk of hepatitis C infection in a cohort of young adult injection drug users, Chicago 1997-1999
35. A risk profile of street youth in northern California: Implications for gender-specific human immunodeficiency virus prevention
36. Psychosocial histories, social environment, and HIV risk behaviors of injection and noninjection drug using homeless youths
37. Prevalence of sexual risk behaviour and substance use among runaway and homeless adolescents in San Francisco, Denver, and New York City
38. Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California
39. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
40. Tattooing as a risk of hepatitis C virus infection
41. Epidemiology of hepatitis C in the East
42. Risk factors for hepatitis C virus infection in United States blood donors
43. Factors associated with prevalent hepatits C: Differences among young adult injection drug users in lower and upper Manhattan, New York City
44. Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999
45. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users
46. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study
47. Sharing of drug preparation equipment a risk factor for hepatitis C
48. Diagnostic tests for hepatitis C
49. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990
50. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992
51. Long-term trends in self-reported HIV risk behavior: Injection drug users in Los Angeles, 1987 through 1995
52. Maximum impact of HIV prevention measures targeted at injecting drug users
53. Natural history of hepatitis C
54. Pathogenesis, natural history, treatment, and prevention of hepatitis C
55. 45-Year follow-up of hepatitis C virus infection in healthy young adults
56. The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not